Call Us!
SlimFitRx™ Weight Loss Program
Compounded Semaglutide, Tirzepatide
Weight loss is a complex and challenging journey for many individuals, often requiring significant lifestyle changes and dedication. While there are various approaches to weight loss, including diet modification, exercise, and behavior therapy, some people may need additional support to achieve their desired weight goals. This is where SlimFitRx™ comes into play.
What is SlimFitRx?™
It is a medication-based weight loss program designed to treat men and women who are obese, or are overweight and have a certain risk factors, or who simply have excessive weight that they are unduly bothered by it.
The program relies on prescription medication such as semaglutide or tirzepatide or its compounded version, used in conjunction with lifestyle modification such as healthy diets and regular exercise program.
What are These Medications?
Semaglutide is a pharmaceutical product that has gained significant attention and popularity in recent years due to its significant impact on weight loss. It belongs to a class of medications called glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are primarily used for the treatment of type 2 diabetes but have also shown significant results in helping individuals achieve sustainable weight loss.
Semaglutide works by mimicking the effects of a naturally occurring hormone called glucagon-like peptide-1 (GLP-1) in the body. GLP-1 helps regulate blood sugar levels. It also promotes satiety, reduces hunger, slows down stomach emptying and increases feelings of fullness.
How Effective is SlimFitRx™ Program?
Many patients lose considerable weight, averaging 15% of body mass from using semaglutide and 22% from using tirzepatide. Individual results may vary, however, and the effectiveness may depend on various factors such as dosage, compliance to treatment plan, genetics and lifestyle changes.
How long does it take to show results?
The effects of semaglutide or tirzepatide on weight reduction can vary from person to person. Some individuals may start noticing a decrease in weight within a few weeks of starting treatment, while others may take longer to see noticeable results. It is important to remember that individual responses can differ.
What are the side-effects?
The side-effects are typically mild, especially when compared to the complications associated with overweight and obesity.
Gastrointestinal problems are the most common side-effects and may include nausea, indigestion, bloating, gas, vomiting, constipation, diarrhea.
You may be able to reduce these side-effects by commencing on a lower dose and slowly increasing the amount to the full therapeutic level.
Other side-effects may include headache and dizziness.
Contraindications:
- Known hypersensitivity to the drug or any of its components
- Personal or family history of MEN 2 (multiple endocrine neoplasia syndrome type 2) or medullary thyroid cancer
Relative Contraindications:
- History of pancreatitis.
In rare cases, these medications may cause or exacerbate symptoms of pancreatitis • - History of retinopathy.
Patients should have thorough eye examination and follow-up with their eye specialists if they are using these medications
Important considerations:
- Medical supervision: SlimFitRx™ Program is a medically supervised program. It is important to discuss any preexisting conditions with your physician before taking these drugs, as well as any concerns you may have during treatment.
Remember that having a full health picture is vital for safe use of medication-based weight loss program - Lifestyle modifications: The use of medication should also be accompanied by lifestyle modifications, such as:
- Adopting healthy dietary habits which include a balanced and nutritious diet, limiting processed foods and sugary beverages, and incorporating more fruits, vegetables, and whole grains into your meals.
- Maintaining regular physical activity which includes aerobic activities, strength training, and regular moderate-intensity workouts.
How Much Does it Cost?
The FDA approved semaglutide for treatment of type 2 diabetes under the brand name, Ozempic™ in 2017 and that same semaglutide is approved for treatment of obesity under the brand name, Wegovy™ in 2021.
The FDA also approved tirzepatide for treatment of type 2 diabetes under the brand, Mounjaro™ in 2022 and is expected to approve the same drug for weight loss under a different brand by end of 2023.
Using brand name medication such as Ozempic™ or Wegovy™ without insurance coverage could cost several thousand dollars a month, depending on the doses needed. There is no generic form for semaglutide or tirzepatide.
SlimFitRx™ Program offers compounded medications prepared by specialized compounding pharmacies. Compounding is a process that involves combining, mixing or altering the ingredients to create the medication. These compounded medications are often in the salt forms, such as semaglutide acetate, not the base form as in the brand name ones and are often combined with Vitamin B6 which can effectively help reduce the gastrointestinal side-effects.
Patients who enroll in SlimFitRx™ Program can access these medications for as low as a few hundred dollars a month, while benefitting the same clinical outcomes as brand name ones.
In conclusion, SlimFitRx™ Program, via Semaglutide and Tirzepatide, is emerging as a game changer in our efforts to lose weight. These medications can promote significant weight loss safely and effectively. Further, they can reduce risk of cancer, diabetes and heart disease, in people who are obese or overweight. Please consult our physicians to see if SlimFitRx™ Program is right for you.
References
Muller TD, Bluher M, Tschop MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21:201–223. doi: 10.1038/s41573-021-00337-8. - DOI - PMC - PubMed
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398:1811–1824. doi: 10.1016/S0140-6736(21)02188-7. - DOI - PubMed
Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503–515. doi: 10.1056/NEJMoa2107519. DOI - PubMed
Ludvik B, Giorgino F, Jodar E, Frias JP, Fernandez Lando L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398:583–598. doi: 10.1016/S0140-6736(21)01443-4. - DOI - PubMed
Rosenstock J, Wysham C, Frias JP, Kaneko S, Lee CJ, Fernandez Lando L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398:143–155. doi: 10.1016/S0140-6736(21)013246. - DOI - PubMed
